- Home
- ONCO vs NDRA Comparison
ONCO vs NDRA Comparison
Compare ONCO & NDRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONCO
- NDRA
- Stock Information
- Founded
- ONCO 2018
- NDRA 2007
- Country
- ONCO United States
- NDRA United States
- Employees
- ONCO N/A
- NDRA N/A
- Industry
- ONCO Biotechnology: Pharmaceutical Preparations
- NDRA Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- ONCO Health Care
- NDRA Health Care
- Exchange
- ONCO Nasdaq
- NDRA Nasdaq
- Market Cap
- ONCO 4.7M
- NDRA 3.9M
- IPO Year
- ONCO 2022
- NDRA 2017
- Fundamental
- Price
- ONCO $3.82
- NDRA $6.45
- Analyst Decision
- ONCO
- NDRA Strong Buy
- Analyst Count
- ONCO 0
- NDRA 1
- Target Price
- ONCO N/A
- NDRA $38.00
- AVG Volume (30 Days)
- ONCO 266.4K
- NDRA 40.9K
- Earning Date
- ONCO 08-14-2025
- NDRA 11-14-2025
- Dividend Yield
- ONCO N/A
- NDRA N/A
- EPS Growth
- ONCO N/A
- NDRA N/A
- EPS
- ONCO N/A
- NDRA N/A
- Revenue
- ONCO $1,326,959.00
- NDRA N/A
- Revenue This Year
- ONCO N/A
- NDRA N/A
- Revenue Next Year
- ONCO N/A
- NDRA N/A
- P/E Ratio
- ONCO N/A
- NDRA N/A
- Revenue Growth
- ONCO N/A
- NDRA N/A
- 52 Week Low
- ONCO $2.45
- NDRA $2.90
- 52 Week High
- ONCO $552.50
- NDRA $22.68
- Technical
- Relative Strength Index (RSI)
- ONCO 60.58
- NDRA 68.71
- Support Level
- ONCO $3.02
- NDRA $5.30
- Resistance Level
- ONCO $3.24
- NDRA $6.45
- Average True Range (ATR)
- ONCO 0.32
- NDRA 0.40
- MACD
- ONCO 0.04
- NDRA 0.12
- Stochastic Oscillator
- ONCO 80.46
- NDRA 73.45
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
About NDRA ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI at the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.